Jiang Y, Zhang J, Liu Z, Zhang J, Yu X, Lin D
BMC Cancer. 2025; 25(1):108.
PMID: 39838412
PMC: 11748843.
DOI: 10.1186/s12885-025-13501-9.
Kakizuka T, Nakaoka H, Hara Y, Ichiraku A, Arai Y, Itoga H
Sci Rep. 2025; 15(1):1422.
PMID: 39789232
PMC: 11717926.
DOI: 10.1038/s41598-025-85759-9.
Liu S, Ai Z, Hu Y, Ren G, Zhang J, Tang P
NPJ Sci Food. 2024; 8(1):105.
PMID: 39702347
PMC: 11659631.
DOI: 10.1038/s41538-024-00341-3.
Li X, Dong J, Li B, Aimei O, Sun Y, Wu X
Dose Response. 2024; 22(4):15593258241301525.
PMID: 39588071
PMC: 11587189.
DOI: 10.1177/15593258241301525.
Pati P, Karkampouna S, Bonollo F, Comperat E, Radic M, Spahn M
Nat Mach Intell. 2024; 6(9):1077-1093.
PMID: 39309216
PMC: 11415301.
DOI: 10.1038/s42256-024-00889-5.
Association between tumor necrosis factor receptor 2 and progression and poor prognosis of tumor stage 2‑3 esophageal squamous cell carcinoma and stratified analysis.
Liu Z, Ren M, Jia S, Qiao S, Yang D
Oncol Lett. 2024; 28(5):505.
PMID: 39233825
PMC: 11369855.
DOI: 10.3892/ol.2024.14638.
Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology.
Mi H, Sivagnanam S, Ho W, Zhang S, Bergman D, Deshpande A
Brief Bioinform. 2024; 25(5).
PMID: 39179248
PMC: 11343572.
DOI: 10.1093/bib/bbae421.
Evolution of phenotypic plasticity leads to tumor heterogeneity with implications for therapy.
Syga S, Jain H, Krellner M, Hatzikirou H, Deutsch A
PLoS Comput Biol. 2024; 20(8):e1012003.
PMID: 39121170
PMC: 11338451.
DOI: 10.1371/journal.pcbi.1012003.
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.
Bakht M, Beltran H
Nat Rev Urol. 2024; 22(1):26-45.
PMID: 38977769
PMC: 11841200.
DOI: 10.1038/s41585-024-00900-z.
Metabolic Insight into Glioma Heterogeneity: Mapping Whole Exome Sequencing to In Vivo Imaging with Stereotactic Localization and Deep Learning.
Servati M, Vaccaro C, Diller E, Pellegrino da Silva R, Mafra F, Cao S
Metabolites. 2024; 14(6).
PMID: 38921472
PMC: 11205750.
DOI: 10.3390/metabo14060337.
Evolutionary screening of precision oncology biomarkers and its applications in prognostic model construction.
Zhang Z, Zhang K, Liao X, Quan Y, Zhang H
iScience. 2024; 27(6):109859.
PMID: 38799582
PMC: 11126775.
DOI: 10.1016/j.isci.2024.109859.
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.
Sujit S, Aminu M, Karpinets T, Chen P, Saad M, Salehjahromi M
Nat Commun. 2024; 15(1):3152.
PMID: 38605064
PMC: 11009351.
DOI: 10.1038/s41467-024-47512-0.
Analysis and Validation of Tyrosine Metabolism-related Prognostic Features for Liver Hepatocellular Carcinoma Therapy.
Cui Z, Liu C, Li H, Wang J, Li G
Curr Med Chem. 2024; 32(1):160-187.
PMID: 38415454
DOI: 10.2174/0109298673290101240223074545.
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.
Al Hmada Y, Brodell R, Kharouf N, Flanagan T, Alamodi A, Hassan S
Cancers (Basel). 2024; 16(2).
PMID: 38275910
PMC: 10814963.
DOI: 10.3390/cancers16020470.
Spatial mapping of tumor heterogeneity in whole-body PET-CT: a feasibility study.
Jonsson H, Ahlstrom H, Kullberg J
Biomed Eng Online. 2023; 22(1):110.
PMID: 38007471
PMC: 10675915.
DOI: 10.1186/s12938-023-01173-0.
Phenotypic maps for precision medicine: a promising systems biology tool for assessing therapy response and resistance at a personalized level.
Bhattacharyya S, Ehsan S, Karacosta L
Front Netw Physiol. 2023; 3:1256104.
PMID: 37964768
PMC: 10642209.
DOI: 10.3389/fnetp.2023.1256104.
Engineering Heterogeneous Tumor Models for Biomedical Applications.
Wu Z, Huang D, Wang J, Zhao Y, Sun W, Shen X
Adv Sci (Weinh). 2023; 11(1):e2304160.
PMID: 37946674
PMC: 10767453.
DOI: 10.1002/advs.202304160.
From Chaos to Opportunity: Decoding Cancer Heterogeneity for Enhanced Treatment Strategies.
Ottaiano A, Ianniello M, Santorsola M, Ruggiero R, Sirica R, Sabbatino F
Biology (Basel). 2023; 12(9).
PMID: 37759584
PMC: 10525472.
DOI: 10.3390/biology12091183.
Nurturing next generation physicians: A new Israeli healthtech fellowship.
Rosen-Zvi M, Frimer M, Shoher A, Liel-Cohen N, Sprecher E, Mizrahi Reuveni M
iScience. 2023; 26(9):107550.
PMID: 37744411
PMC: 10517394.
DOI: 10.1016/j.isci.2023.107550.
Disentangling the roles of aneuploidy, chromosomal instability and tumour heterogeneity in developing resistance to cancer therapies.
Andrade J, Gallagher A, Maharaj J, McClelland S
Chromosome Res. 2023; 31(4):28.
PMID: 37721639
PMC: 10506951.
DOI: 10.1007/s10577-023-09737-5.